How cells 'hide'
potentially dangerous DNA segments

Friday, April 10,
2009
The DNA in the 23 pairs of chromosomes in each of the billions of
cells of the human body is so tightly packed that it would measure
six feet in length if stretched end to end. A genome of this size
can squeeze into a cell's tiny nucleus because it is compressed
into highly condensed chromatin fibers by proteins called
histones.
All chromatin in the cell nucleus represents a massive condensation
of the genetic material. But a portion of it might well be called
super-condensed; it forms a kind of chromatin called
heterochromatin. The genes contained within these portions of the
genome are effectively "silenced" because they cannot be accessed
by the cell's DNA-activating machinery. These "hidden" parts of the
genome also include highly repetitive, gene-poor, regions. Some of
these, if unpacked, would set loose DNA sequences that act like
parasites – able to jump around to other areas, sometimes randomly,
unleashing genetic chaos.
To assemble heterochromatin, numerous molecules participate in an
elaborate series of maneuvers that have gradually come to light.
"But scientists have been a little hazy on the initial steps and
requirements that get this process going," says Professor Leemor
Joshua-Tor, Ph.D., of Cold Spring Harbor Laboratory (CSHL). She and
her research team have now brought this process into sharper focus
by identifying a critical requirement for heterochromatin to be
established in the nucleus.
In a report that appears online on April 9th in the journal
Molecular Cell, they show that the assembly of heterochromatin
depends on the strength with which a protein called Chp1 binds to a
specific target site located on a histone protein that has attached
to the double helix.
RNAi's role in heterochromatin formation
In a typical chromosome -- roughly the shape of a bow-tie –
heterochromatin is concentrated at (and supports the structure of)
the centromere, the bow's central "knot." Since centromeres are
crucial for genomic integrity, aberrant heterochromatin formation
can result in genetic anomalies and diseases such as cancer.
Heterochromatin depends on the density of chemical "marks" that are
added to histones at specific locations on their tail ends. These
marks consist of methyl groups that get attached to the tail of one
of the histones, histone H3, at a specific spot – the ninth
residue, which happens to be the amino acid lysine (K). This mark
is therefore called H3K9me.
In fission yeast, a model system used for studying heterochromatin
mechanisms because of its comparative simplicity, the precise
pattern of methylation depends on a process called RNA
interference, or RNAi. It involves a host of players: the enzyme
that copies DNA into RNA, which is diced into short segments called
short interfering RNAs, or siRNAs; a part of the RNAi machinery
known as the RITS complex; and various enzymes that are able to
alter the configuration of chromatin.
A debate over recruitment
"In trying to understand the interplay between each of these
components," explains Joshua-Tor, "there has been a longstanding
debate over how the RITS complex initially gets recruited to the
regions at the centromere that are destined to become
heterochromatin."
At first, scientists thought that the siRNA molecules acted as
guides to recruit RITS. After latching on to the chromatin, RITS
was in turn thought to recruit the other components: the enzyme
that adds the methyl marks; and the protein Chp1, which acts as a
molecular "velcro" to keep the RITS complex firmly attached to the
methyl-decorated chromatin.
The importance of binding strength
The CSHL team in collaboration with the team of Janet Partridge at
St. Jude's Children's Research Hospital, Memphis, has now found
that siRNAs cannot do the job of heterochromatin assembly by
themselves. Rather, the siRNA-guided interaction relies on the
strength with which the velcro-like protein Chp1 binds to
methylated chromatin.
"We found that a part of Chp1 known as the chromodomain binds with
high affinity (or strength) to methylated chromatin," explains
Thomas Schalch, Ph.D., a postdoctoral researcher in the Joshua-Tor
lab who led the current study. By teasing apart the origin of this
unique affinity, the CSHL team stumbled across Chp1 mutants that
would produce siRNAs but could not assemble heterochromatin.
"These results lead us to think that the tight interaction between
RITS and the methyl marks is a requirement at least as important as
the availability of siRNA," Schalch says.
A crystal structure provides the answer
The team wanted to know the exact points of contact between Chp1
and its target and how these interactions contributed to the
strength of binding. For these answers, Schalch and the CSHL team
made use of Joshua-Tor's expertise in X-ray crystallography – the
science of determining the exact position of atoms and bonds within
a molecule by creating a crystal, which is then probed with
powerful x-rays.
Disrupting each point of interaction between Chp1 and its target by
engineering various mutations into the Chp1 protein decreased the
strength of binding to different levels. Even a five-fold decrease
in binding strength prevented the mutation-bearing cells from
assembling new heterochromatin, even though some of the mutants
were able to generate siRNAs.
This work reveals that siRNAs cannot by themselves establish
heterochromatin when Chp1's binding to H3K9me – the methylated
chromatin – is impaired. Whether this mechanism of heterochromatin
assembly discovered in yeast also occurs in mammalian cells is
unclear at this point, according to Schalch, as a mammalian
equivalent to Chp1 has not been found. "But we've now identified a
fingerprint for the high-affinity interaction between a
chromatin-binding protein and its 'marked', or methylated, target,"
says Schalch. "This may help us identify Chp1-like proteins in
mammalian cells."
###
Cold Spring Harbor Laboratory
Thanks to Cold Spring Harbor
Laboratory for this article.